期刊文献+

血清中性粒细胞/淋巴细胞比值与胃肠间质瘤患者预后的关系及其临床意义 被引量:4

Relation Between Blood Neutrophil-to-Lymphocyte Ratio and Prognostic of Patients with Gastrointestinal Stromal Tumor and Its Clinical Significance
原文传递
导出
摘要 目的检测中性粒细胞/淋巴细胞比值(NLR)在胃肠间质瘤(GIST)患者术前血清中的高低情况并分析其与预后的关系。方法采用回顾性的方法分析符合纳入条件的42例GIST患者术前3 d血常规中NLR及其病理切片中各免疫组织化学检测结果,并通过生存分析了解NLR与GIST患者预后的关系。结果 42例GIST患者中有22例NLR≥2.5(高NLR组),20例NLR<2.5(低NLR组)。NLR与GIST患者临床病理特征中核分裂像(χ2=9.45,P=0.002)和肿瘤大小有关(P=0.041)。高NLR组的GIST患者的3年生存率明显低于低NLR组的患者,其差异有统计学意义(χ2=5.44,P=0.022)。单因素分析结果显示,NLR、核分裂像及肿瘤大小与患者3年生存率有关(P<0.05);多因素分析结果显示,NLR和核分裂像是GIST患者3年生存率的独立危险因素(P=0.018,P=0.000)。结论 NLR和细胞核分裂像是影响GIST患者预后的独立危险因素,其对GIST患者的预后有一定预测价值。 Objective To investigate preoperative blood neutrophil-to-lymphocyte ratio(NLR)in patients with gastrointestinal stromal tumor(GIST)and analyze the relationship of the NLR to prognosis.Methods The data of NLR of peripheral blood samples on 3 d before surgery and the results of immunohistochemistry of 42 patients with GIST were analyzed respectively,the relation between the NLR and the prognosis of patients with GIST was understood by the survival analysis.Results The patients with high NLR(NLR≥2.5)was found in 22 cases,low NLR(NLR2.5)in 20 cases.The NLR was related to mitotic figures(χ 2 =9.45,P=0.002)and tumor size(P=0.041).The 3-year survival rate of the patients with high NLR was shorter than that of the low NLR(χ 2 =5.44,P=0.022).The 3-year survival rate was associated with NLR,mitotic figures,and tumor size(P0.05)in univariate analysis.The NLR and mitotic figures were independent prognostic indicators of 3-year survival(P=0.018,P=0.000)in Cox multivariate analysis.Conclusion Blood NLR and mitotic figures have some predictive value for the prognosis of patients with GIST.
出处 《中国普外基础与临床杂志》 CAS 2013年第8期910-914,共5页 Chinese Journal of Bases and Clinics In General Surgery
关键词 中性粒细胞 淋巴细胞比值 胃肠间质瘤 预后 Neutrophil-to-lymphocyte ratio Gastrointestinal stromal tumor Prognosis
  • 相关文献

参考文献26

  • 1Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors [ J]. Nat Med, 2011, 17(6) : 700-707.
  • 2马晋平,王智,林建伟,吴恺明,陈剑辉,陈创奇,蔡世荣,何裕隆,詹文华.中性粒细胞/淋巴细胞比值在胃癌预后评估中的应用[J].中华胃肠外科杂志,2011,14(12):944-947. 被引量:34
  • 3Ohno Y, Nakashima J, Ohori M, et aL Pretreatment neutrophil-to- lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma [J]. J Urol, 2010, 184(3): 873-878.
  • 4Fletcher CD, Berman JJ, Corless C, etaL Diagnosis of gastroin- testinal stromal tumors a consensus approach [J]. Hum Pathol, 2002, 33(5): 459-465.
  • 5卢震海,伍小军,方淯靖,潘志忠,万德森.胃肠间质瘤的外科治疗及预后分析[J].中华胃肠外科杂志,2011,14(10):778-780. 被引量:7
  • 6张洪静,黄娟,敖平,黄子星,赵爽.64层螺旋CT对胃间质瘤的诊断价值[J].中国普外基础与临床杂志,2012,19(8):885-889. 被引量:5
  • 7Balkwill F, Mantovani A. Inflammation and cancer: back to Vir- chow? [J]. Lancet, 2001, 357(9255): 539-545.
  • 8Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis [J]. Blood, 2009, 114 (2): 357-359.
  • 9Maheswaran S, Haber DA. Circulating tumor ceils: a window into cancer biology and metastasis [J]. Curr Opin Genet Dev, 2010, 20(1): 96-99.
  • 10Coussens LM, Werb Z. Inflammation and cancer [J]. Nature, 2002, 420(6917): 860-867.

二级参考文献46

  • 1Xiao-LiChen,Bao-ShanSu,Run-QinSun,JunZhang,Yi-LiWang.Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma[J].World Journal of Gastroenterology,2005,11(8):1228-1231. 被引量:30
  • 2岳松伟,高剑波,杨学华,陈学军,周志刚,郭华.胃间质瘤的螺旋CT诊断价值[J].中国医学影像技术,2006,22(7):1035-1038. 被引量:33
  • 3Parfitt JR, Streutker C J, Riddell RH, et al. Gastrointestinal stromal tumors: a contemporary review. Pathol Res Pract, 2006,202(12) : 837-847.
  • 4Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol, 2008,15( 1 ) : 52-59.
  • 5Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol, 2005,16(4) :566-578.
  • 6Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009,20 (Suppl 4 ) :64-67.
  • 7NCCN. The NCCN soft tissue sarcoma clinical practice guidelines in oncology (version 1, 2011). (C) 2011 National Comprehensive Cancer Network, Inc. http ://www.necn.org.
  • 8Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol, 2007,14( 1 ): 14-24.
  • 9Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy:Current role in the management of GIST. Int J Cancer, 2011, In press.
  • 10Jamali FR, Darwiche SS, E1-Kinge N, et al. Disease progression following Imatinib failure in gastrointestinal stromal tumors: role of surgical therapy. Ongologist, 2007,12(4) :438-442.

共引文献48

同被引文献50

  • 1王智,马晋平,林建伟,陈创奇,蔡世荣,何裕隆.术前中性粒细胞与淋巴细胞比值与结直肠癌患者预后的关系[J].消化肿瘤杂志(电子版),2011,3(4):246-250. 被引量:17
  • 2Hidalgo M. Pancreatic cancer[J].N Engl J Med, 2010, 362 (17):1605-1617.
  • 3Helm O, Held-Feindt J, Grage-Griebenow E, et al. Tumor-asso-ciated macrophages exhibit pro- and anti-inflammatory propertiesby which they impact on pancreatic tumorigenesis[J].Int J Cancer, 2014, 135(4):843-861.
  • 4Hamada S, Masamune A, Shimosegawa T. Inflammation and pancreatic cancer:disease promoter and new therapeutic target[J].J Gastroenterol, 2014, 49(4):605-617.
  • 5Steele CW, Jamieson NB, Evans TR, et al. Exploiting inflamma-tion for therapeutic gain in pancreatic cancer[J].Br J Cancer, 2013, 108(5):997-1003.
  • 6Wang W, Hodkinson P, McLaren F, et al. Histologic assessmentof tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer[J].Chest, 2013, 143(1):146-151.
  • 7Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comesof age[J].Nature, 2011, 480(7378):480-489.
  • 8Vanneman M, Dranoff G. Combining immunotherapy and targetedtherapies in cancer treatment[J].Nat Rev Cancer, 2012, 12(4):237-251.
  • 9An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyteratio predicts survival in advanced pancreatic cancer[J].Biomar-kers, 2010, 15(6):516-522.
  • 10Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lympho-cyte ratio is a poor prognostic factor in patients with primaryoperable and inoperable pancreatic cancer[J].Br J Cancer, 2013, 109(2):416-421.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部